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V
isceral leishmaniasis (VL), commonly known as kala-
azar, from the Hindu vernacular, is a human systemic 
disease caused by parasitic protozoan species of the 
genus Leishmania. Transmitted by the bite of the tiny and 
seemingly innocuous female phlebotomine sandﬂ  y (Figure 
1), the parasite enters macrophages, where it multiplies and 
establishes the infection (Figure 2). 
A multitude of clinical features of the disease ensue 
gradually, the most important being splenomegaly, recurring 
and irregular fever, anaemia, pancytopenia, weight loss, and 
weakness. Unlike malaria, there is no early dramatic fever 
to announce its arrival; the presentation is insidious, with 
symptoms appearing over a period of weeks or even months. 
Affected patients become progressively more anaemic, 
weak, cachectic, and susceptible to intercurrent infections. 
The disease is a silent killer, invariably killing almost all 
untreated patients [1]. VL affects not only the weakest in the 
community, such as children and those weakened by other 
diseases such as HIV and tuberculosis, but also healthy adults 
and economically productive social groups. 
An estimated 500,000 new cases of VL occur each year, 
and a tenth of these patients will die [2]. The actual death 
toll from the disease may be higher than this estimate, 
considering the existence of unidentiﬁ  ed VL foci. 
Some 90% of those affected by the disease live in ﬁ  ve 
countries: India (especially Bihar), Bangladesh, Nepal, 
(northeastern) Brazil, and Sudan [2]. VL often exists in areas 
that are either remote or not easily accessible, and where 
health facilities are barely available or inadequate. Those 
most likely to be infected are people who are poor, living in 
villages far from roads and health-care centres. Patients from 
such remote communities often die in the villages without 
seeking treatment. Some may attempt to report to distant 
health-care centres, but in many cases it is simply too late. 
Even if they can make the journey to a hospital, they would 
still succumb to the illness because of the absence of anti-
leishmanial drugs. Thus, many decide to stay at home until 
they die. But in doing so, they act as a reservoir of infection, 
passing on the parasite to family and neighbours through the 
bite of sandﬂ  ies. 
At present, approaches to the control of VL are varied. 
This variety is dictated ﬁ  rst and foremost by the diverse 
epidemiological patterns of the disease, which range from 
domestic zoonosis (see Glossary) involving the dog (the 
Mediterranean littoral) or sylvatic zoonosis (South America, 
and possibly Africa) to anthroponosis (India and Africa). 
The major epidemics of VL that have occurred in India 
and Africa have primarily been a result of human-to-human 
transmission, be it in a primarily anthroponotic or zoonotic 
focus. Knowledge of the epidemiology, and ecological types, 
of VL is of paramount importance in designing a sound VL 
control strategy. 
Identifying Patients and Mapping the Distribution: 
The Need for Improved Tools 
Most VL infections occur in remote geographical areas 
where health facilities are not well established and where the 
infections often co-exist with malaria and other debilitating 
parasitic infections. Under these circumstances, the disease 
usually presents a diagnostic dilemma. 
To alleviate this difﬁ  culty, health workers need to be 
provided with up-to-date information on the geographical 
distribution of VL in endemic countries. The mapping of 
VL is a complex undertaking, as the distribution of the 
disease is multifocal in nature, with remarkable variation in 
its prevalence and incidence. Moreover, most clinical cases 
are neither treated nor reported. This difﬁ  culty is further 
compounded by the fact that most infections of Leishmania 
are subclinical. 
The main activities of mapping involve active surveillance 
by case-ﬁ  nding, leishmanin skin test surveys, and 
serological screening of populations. Effective mapping 
activities will also require additional information about 
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the sandﬂ  y. As capacities for undertaking such surveys 
are limited, mapping activities may be based on the use of 
the Geographic Information System (GIS), by which risk 
areas of VL can be predicted in areas where surveillance 
data are not readily available [3,4]. Using GIS, it is possible 
to produce predicted-risk maps of the disease, based on 
statistical associations between the spatially comprehensive 
environmental data available from satellites and previous 
knowledge about disease distribution. GIS has been used to 
produce risk maps of VL in some countries, and it is hoped 
that the maps will assist in planning future vector-control 
programmes.
The leishmanin skin test has been used for geographical 
mapping and for epidemiological description of 
transmission patterns [5–7]. However, its large-scale use has 
been frustrated by the absence of a standardised test antigen 
and models for interpretation of ﬁ  eld data. Periodic active 
case-ﬁ  nding surveys are often used in mapping activities. 
But the labour-intensive nature of the endeavour does not 
permit wide coverage. The development of simple and 
robust screening techniques, such as the fast agglutination 
screening test (FAST), can be a useful addition for mapping 
activities [8]. Using FAST, large numbers of blood samples 
can be tested in a short time and can provide an indicator of 
past or present disease or infection. Field experiences with 
FAST have indicated the need for further improvements of 
the test with respect to robustness as well as cost. Other test 
systems for use in epidemiological mapping are yet to be 
developed. 
Estimates of Incidence
Incidence of VL varies from place to place depending 
on the epidemiological characteristics. Areas of sporadic 
endemicity (low incidence) and endemo-epidemicity (high 
incidence) are known to exist. High incidence rates of 
VL are common in areas where human populations are 
despoiled by social instability, war, and migration. However, 
accurate data on the burden of VL do not exist in many 
VL foci, as large proportions of VL cases are not recorded. 
Researchers and clinicians working in the ﬁ  eld estimate that 
in some countries less than 20% of patients are currently 
being reached, even though this may vary from country to 
country. 
The failure of governments to reach patients is one of 
the main reasons for the increasing death toll and the ever-
increasing incidence of the disease. Control strategies for 
VL need to highlight the importance of treatment not only 
to reduce morbidity and mortality but also to prevent the 
accumulation of cases. These strategies require the availability 
of simple diagnostic tools and affordable, easy-to-administer 
drugs. 
Conventional Diagnostics: 
Invasive and Potentially Dangerous
Demonstration of parasites in stained smears of tissue 
aspirates from spleen, bone marrow, or lymph node remains 
the most accurate (speciﬁ  c) method available for diagnosis 
of VL. Spleen and bone marrow are both superior to lymph 
node but more invasive. Obtaining aspirates from the 
spleen can be dangerous in patients with haematological 
complications. Culture of the Leishmania parasite from tissue 
aspirates in Novy-MacNeal-Nicolle or Schneider’s insect 
medium supplemented with 10% v/v foetal calf serum, if 
properly performed, is a more sensitive technique. 
Serological tests based on the detection of speciﬁ  c humoral 
antibodies are less invasive. Such tests include indirect 
ﬂ  uorescent antibody test, direct agglutination test (DAT), 
enzyme-linked immunosorbent assay, and rK39 dipstick 
test [9,10]. However, these tests, with the exception of the 
last, require trained personnel and considerable laboratory 
facilities. False positives can occur when these tests are used. 
Furthermore, serological tests may remain positive after 
successful treatment and give false negative results in patients 
with VL and HIV co-infection. Nonetheless, serological tests 
have been used in screening patients (to exclude other 
causes of febrile hepatosplenomegaly) and to support clinical 
diagnosis of VL. 
Control programmes for VL in some countries use 
diagnostic algorithms that also include DAT and the 
dipstick test systems. DAT has been used widely under 
ﬁ  eld conditions. The existing dipstick test systems (such as  
rK39) are attractive options. Preliminary ﬁ  eld trials of rK39 
have shown promising but geographically variable results. 
Together with DAT, the rK39 dipstick test and urine antigen 
detection tests are currently under evaluation by the World 
Health Organization in different countries. The development 
of a sensitive, speciﬁ  c, simple, and affordable test for use in 
ﬁ  eld settings will be a crucial step in the control of VL. Thus, 
the need to improve rK39, and the development of new 
dipstick systems, is vital.  
DOI: 10.1371/journal.pmed.0020211.g001
Figure 1. Female Phlebotomus sp. Sandﬂ  y
(Photo: WHO/CDC)
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Current Treatments: Old, Toxic, and Difﬁ  cult to Deliver
For many decades, the treatment of VL has been based on 
pentavalent antimonials, such as sodium stibogluconate 
(Pentostam) or meglumine antimoniate (Glucantime), given 
intramuscularly or intravenously for one month.
Discovered 60 years ago, sodium stibogluconate remains 
the mainstay treatment of VL despite its cardiotoxicity in 
some patients. Treatment requires 30 days of intramuscular 
or intraveneous injections in a hospital setting. Although it 
is still effective in most endemic countries, with 95% cure 
rates, resistance is increasing in some regions, especially in 
northern Bihar, India, where it is up to 65% [11]. 
Other drugs, such as amphotericin B (Fungizone), liposomal 
amphotericin B (AmBisome), and miltefosine (Impavido), are 
available for the treatment of VL but are not optimal due to 
problems of toxicity, high price, or difﬁ  culty in administration. 
Amphotericin B. This drug is highly efﬁ  cacious but is 
associated with serious side effects and can only be given in a 
hospital setting. 
Liposomal amphotericin B. This is considered to be the 
most effective of currently available anti-leishmanial drugs, 
but it is prohibitively expensive and has to be administered 
intravenously, making treatment more difﬁ  cult under ﬁ  eld 
conditions. However, recent clinical studies in India involving 
203 patients showed that liposomal amphotericin B could 
be used as a single-dose treatment regime with a cure rate of 
90% [12]. Such data are needed from African endemic areas, 
as it might be that response to liposomal amphotericin B can 
vary from species to species and in different populations. The 
varying doses of liposomal amphotericin B needed to achieve 
a cure in different endemic countries needs careful attention. 
Miltefosine. This drug is effective against VL but is 
expensive and teratogenic [13], so it cannot be used to 
treat women of childbearing age. There is a theoretical 
risk of resistance developing quickly to it, if it is not used 
in combination with other drugs. Miltefosine is registered 
in India for ﬁ  rst-line treatment of VL, and in Europe for 
treatment of VL in patients co-infected with HIV, especially in 
those patients unresponsive to other treatments [14].
Developing New Drugs
Given the problems associated with the handful of currently 
available drugs for VL, new and improved treatments to 
replace or complement existing therapy are needed urgently. 
Drug combinations for treating VL should provide advantages 
of protection from parasite resistance, as well as a reduction 
in treatment duration and overall toxicity. 
Paromomycin (also known as aminosidine), an antibiotic 
of the aminoglycoside family with proven anti-leishmanial 
activity, is a candidate drug for treatment of VL. Early 
clinical studies in Kenya and India [15–17] have shown that 
this drug is effective in the treatment of VL. The current 
treatment regimen for paromomycin is 21 days when used as 
a single agent, but could be reduced to 17 days when used in 
combination with sodium stibogluconate, as ﬁ  eld experience 
of Médecins Sans Frontières has shown 
(unpublished data). 
The Drugs for Neglected Diseases 
Initiative is currently carrying out 
phase III clinical trials of paromomycin 
in east Africa with a view to registering 
the drug in Ethiopia, Sudan, and 
Kenya. The Institute for OneWorld 
Health, a nonproﬁ  t pharmaceutical 
company, has conducted phase III 
trials of paromomycin and is pursuing 
registration in India (see http:⁄⁄www.
oneworldhealth.org/diseases/
leishmaniasis.php).
Vaccines: Progress and 
Frustrations 
Extensive studies on the mechanisms 
of immuno-pathogenesis and 
protective immunity against 
leishmaniasis, especially in mice, have 
identiﬁ  ed Leishmania species as good 
candidates for vaccine development. 
Leishmania species rarely undergo 
antigenic variation and show extensive 
cross-reactivity between different 
species [18,19]. Furthermore, the 
observation that strong lifelong 
immunity follows after recovery from 
Leishmania infections in humans has 
provided a rationale for designing 
immuno-prophylactic strategies 
against leishmaniasis. It is now a 
well-established fact that protective 
DOI: 10.1371/journal.pmed.0020211.g002
Figure 2. The Life Cycle of Leishmania spp., the Causal Agents of Leishmaniasis
Leishmaniasis is transmitted by the bite of female phlebotomine sandﬂ  ies. The sandﬂ  ies 
inject the infective stage, promastigotes, during blood meals (1). Promastigotes that reach the 
puncture wound are phagocytized by macrophages (2) and transform into amastigotes (3). 
Amastigotes multiply in infected cells and affect different tissues, depending in part on the 
Leishmania species (4). This originates the clinical manifestations of leishmaniasis. Sandﬂ  ies 
become infected during blood meals on an infected host when they ingest macrophages 
infected with amastigotes (5 and 6). In the sandﬂ  y’s midgut, the parasites differentiate into 
promastigotes (7), which multiply and migrate to the proboscis (8).
(Illustration: CDC/Alexander J da Silva/Melanie Moser)
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immunity to leishmaniasis is a function of cell-mediated 
immunity mediated by Type 1 T helper cells. 
Vaccination against cutaneous leishmaniasis (CL) was 
a common traditional practice in the Middle East and the 
Soviet Union [20]. In this practice, scratched tissue from 
active lesions of patients with CL was applied to—or sandﬂ  ies 
were allowed to bite—the skin of healthy individuals. 
Modern approaches of vaccination began by intradermal 
inoculation of live Leishmania in healthy individuals, in an 
attempt to produce mild, self-healing cutaneous lesions 
[21]. This process is often referred to as leishmanization. 
This term is also promiscuously used in the literature to 
describe the traditional practices described above. Self-
healed cutaneous lesions induced by leishmanization usually 
confer protection against new infections. However, when 
leishmanization was applied to large populations, individuals 
developed complicated, severe, or persistent cutaneous 
lesions. Leishmanization has now been abandoned except in 
Uzbekistan [21].
Pioneered by Brazilian investigators, vaccination against 
Leishmania using killed preparations of the parasite stages 
has been attempted since the late 1930s [22]. Since then, 
killed-parasite preparations of various species and strains, 
with or without adjuvants, such as the autoclaved Leishmania 
major (ALM) + Bacille Calmette-Guérin (BCG) vaccines, 
have been extensively studied with variable success in Brazil, 
Venezuela, Colombia, Ecuador, Iran, and Sudan. Even 
though the ﬁ  rst-generation vaccines were safe, efﬁ  cacy 
data have not been convincing [23–27]. In Sudan, alum-
precipitated ALM + BCG vaccine mixture was extensively 
studied and conﬁ  rmed to be superior to ALM + BCG vaccine 
alone [28]. 
In general, ﬁ  rst-generation vaccines, as attractive 
as they were, were met by disappointment from the 
scientiﬁ  c community, resulting in a shift of interest to 
novel approaches of vaccination using second-generation 
vaccines (recombinant molecules, and vaccines with live 
vectors encoding leishmanial antigens and sandﬂ  y salivary 
immunomodulators) [29]. Second-generation vaccines are 
still under development [30] with a number of ongoing 
safety and immunogenicity studies, but efﬁ  cacy data are 
not expected before the next three to ﬁ  ve years. In spite of 
the strong scientiﬁ  c conviction that leishmaniasis is prone 
to control by vaccines, and the extensive vaccine research 
carried out so far, especially in CL, no effective vaccine has 
yet emerged. In particular, there has been little progress 
towards the development of vaccines against VL.  
The Challenges Ahead
Progress towards the discovery of an effective vaccine 
against leishmaniasis has become a snail’s race. Therefore, 
control of leishmaniasis by vaccines remains only a long-
term goal [31]. 
Many leishmaniasis experts nowadays advocate vector 
control, especially for areas of anthroponotic transmission. 
History relates that in India VL was kept under control, 
inadvertently, by the large-scale spraying of DDT during 
anti-malaria campaigns [1]. Recent initiatives of the World 
Health Organization aim to eliminate VL from the Indian 
subcontinent by house-to-house spraying of DDT and to 
reduce epidemic CL in Kabul by a massive provision of 
insecticide-treated nets. Such nets have been used to reduce 
transmission of anthroponotic CL in Afghanistan [32]. 
Personal protection against the bites of Phlebotomus orientalis 
by  insecticide-treated nets was considered a feasible VL 
control approach in Sudan [33]. In Latin America, and 
even more so in southern Europe, where VL is principally 
maintained by the domestic dog, opinions about control of 
VL are divided. In Southern Europe, the situation is further 
compounded by the increasing incidence of adult VL that is 
associated with HIV co-infection. 
In Africa, VL is transmitted mainly in rural areas either 
from a zoonotic source (in sporadic endemic areas) or 
human to human in secondarily anthroponotic foci. Owing 
to the complexity and diversity of transmission patterns, 
but also absence of health-care settings, control of VL in 
the African endemic countries will indeed be challenging. 
In Ethiopia, HIV co-infection in some endemic areas of VL 
ranges from 15%–40%, and is known to be much higher in 
hospitals in big cities. Signiﬁ  cant co-infection rates are being 
documented in Sudan. In these countries, the surveillance of 
HIV co-infection in VL endemic areas has to be an integral 
component of national VL control programmes.
The VL endemic countries provide a unique challenge 
to clinical research and development. Although the 
parasite also occurs in poor semi-urban environments, 
communities of affected patients are generally remote 
and far from health services. Government budgets are 
inadequate and health ministries are overstretched with 
many calls on their resources. In many areas hospital 
facilities are absent or underdeveloped. Tools for screening 
and identiﬁ  cation of patients are inadequate. Current 
diagnostic techniques are invasive and complicated, and 
require trained staff. Treatments are toxic, expensive, and 
difﬁ  cult to administer. These limitations have constrained 
the improvement of access to treatment. On the other hand, 
treatment possibilities by single-dose regimens of liposomal 
amphotericin B as well as the availability of miltefosine as 
an oral treatment of VL may provide opportunities for the 
development of simpliﬁ  ed treatment regimes. 
Vector control can be a useful approach to reduce the 
incidence of VL. Nonetheless, this is easier said than done, 
given the huge amounts of funds required, as well as the 
absence of practical decision support systems in VL endemic 
areas. Aside from availability of up-to-date information on VL 
distribution, health policymakers and health workers should 
be able to carry out efﬁ  cient and effective vector control 
programmes and to properly monitor impact [34]. 
Glossary
Domestic zoonosis: Infection occurring via a domestic animal, 
e.g., dog.
Sylvatic zoonosis: Infection occurring via a feral mammal, e.g., 
mongoose in Sudan.
Anthroponosis: Direct human-to-human transmission by vector 
without an animal reservoir.
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Conclusion
If we are to have an impact on the incidence of the disease 
and curtail the negative socio-economic consequences of VL 
epidemics that deter human development, the international 
community has to address the many issues that we have raised 
in this article. To achieve this complex and difﬁ  cult task, 
substantial funding will be needed, and the task will require 
international cooperation for success.  
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Note Added in Proof
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